Clinical trial · Observational
Ghrelin Levels in Pancreatic Cancer Patients
Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer
NCT00225745CI-TRIAL-00019466completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary outcome measure for this study is plasma ghrelin level.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood draw | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- Pancreatic cancer patients
- interventionNames
- Procedure: Blood draw
- label
- 2
- description
- Healthy controls
- interventionNames
- Procedure: Blood draw
Primary outcomes (1)
- measure
- To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls
- timeFrame
- prior to treatment
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological proof of pancreatic adenocarcinoma * The control are will include healthy age-matched patients without cancer * The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss * Patients must have recovered from any major infections and/or surgical procedures Exclusion Criteria: * Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state * Patients on appetite stimulant and those receiving total parenteral nutrition * Patients who have undergone gastrectomy or those who have gastric ulcers * Patients receiving active chemotherapy * No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.
References
Publications (0)
Data not yet available
No reference posted for this study.